Please login to the form below

Not currently logged in
PMLiVE Top Pharma List

Boehringer Ingelheim

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Boehringer Ingelheim's 2013 sales performance.

Boehringer Ingelheim GmbH

Avenir acquires Cherry, EY wins new account and GK unites businesses

Avenir acquires Cherry, EY wins new account and GK unites businesses

Its goal is to better connect brands with healthcare professionals and patients, and has a robust client listing including the likes of Baxter, Boehringer Ingelheim, Eisai, and Shire.

NHS says Humira biosimilar deal will save £300m

NHS says Humira biosimilar deal will save £300m end. Amgen’s copy Amgevita and Samsung and Biogen’s Imraldi both gained full EU approval last year, and have been joined since by Hyrimoz from Novartis’ Sandoz division, Boehringer

Deal Watch October 2018

With $18B of sales worldwide to protect it is not surprising that AbbVie is taking a firm stance on Humira biosimilars; only Boehringer Ingelheim has elected to go to court to ... AstraZeneca. Anti-NKG2A antibody (monalizumab), IPH5201 (antibody

The Midas Touch

The Midas Touch For example, Boehringer Ingelheim is making choices like this as the company continues its shopping spree in immuno-oncology with the takeover of Vira Therapeutics, a smallish bet with potentially high

Lilly trumpets Trulicity heart data in face-off with Novo Nordisk

Lilly trumpets Trulicity heart data in face-off with Novo Nordisk Boehringer Ingelheim and Lilly’s SGLT2 inhibitor Jardiance (empagliflozin) was the first drug approved by the FDA as being able to reduce the risk of cardiovascular death in patients with type ... Meanwhile Boehringer and Lilly also have new real-world

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts


Add my company
Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...